Xeris Biopharma Holdings, Inc. (XERS)
XERS moved a median of +0.32% 30 minutes after news, and +0.32% by the close. How XERS actually reacts to news — the realized, point-in-time move the market made, measured across 256 labeled events over the last three years with zero look-ahead.
XERS’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.17% | 52% | 254 |
| 30-min | +0.32% | 57% | 255 |
| 60-min | +0.40% | 58% | 255 |
| to close | +0.32% | 57% | 256 |
| Middle 50% of XERS reactions | -0.77% to +1.63% |
|---|---|
| Median reaction (30-min) | +0.32% |
| Measured reactions | 256 |
Half of all Xeris Biopharma Holdings, Inc. news events land between -0.77% and +1.63% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when XERS moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to XERS's baseline. Nothing else.
Recent XERS events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings | Press release | Business Wire | +1.28% | +3.07% | |
| Form 8-K Xeris Biopharma Holdings For: Oct 13 | SEC filing · Form 8-K | SEC EDGAR | +0.59% | -3.08% | |
| Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | Press release | Business Wire | +0.94% | +10.71% | |
| Form 8-K Xeris Biopharma Holdings For: Sep 09 | SEC filing · Form 8-K | SEC EDGAR | -0.47% | -8.54% | |
| Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism | Press release | Business Wire | -0.47% | -8.54% | |
| Xeris Announces Details for XP-8121 Program Overview Webinar | Press release | Business Wire | -0.92% | -0.69% | |
| Form 10-Q Xeris Biopharma Holdings For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.09% | +6.73% | |
| Form 8-K Xeris Biopharma Holdings For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +0.42% | +2.36% | |
| Xeris Biopharma Reports Second Quarter 2026 Financial Results | Press release | Business Wire | +0.42% | +2.36% | |
| Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026 | Press release | Business Wire | +0.36% | +1.45% | |
| Form 8-K Xeris Biopharma Holdings For: Jul 15 | SEC filing · Form 8-K | SEC EDGAR | +0.68% | -2.27% | |
| Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | Press release | Business Wire | +3.17% | +2.07% | |
| Form 8-K Xeris Biopharma Holdings For: Jun 29 | SEC filing · Form 8-K | SEC EDGAR | -0.50% | +0.00% | |
| Xeris Announces Updates to Its Board of Directors | Press release | Business Wire | -0.26% | +2.06% | |
| Form 8-K Xeris Biopharma Holdings For: Jun 10 | SEC filing · Form 8-K | SEC EDGAR | -0.75% | +3.43% | |
| Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS® | Press release | Business Wire | -0.14% | -3.96% | |
| Xeris Biopharma Announces Private Exchange of Convertible Notes | Press release | Business Wire | -0.75% | +3.43% | |
| Form 8-K Xeris Biopharma Holdings For: Jun 04 | SEC filing · Form 8-K | SEC EDGAR | +0.74% | +0.32% | |
| Form 10-Q Xeris Biopharma Holdings For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.22% | -0.61% | |
| Form 8-K Xeris Biopharma Holdings For: May 07 | SEC filing · Form 8-K | SEC EDGAR | -0.45% | -1.04% | |
| Xeris Biopharma Reports First Quarter 2026 Financial Results | Press release | Business Wire | -0.45% | -1.04% | |
| Form ARS Xeris Biopharma Holdings For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.17% | +1.85% | |
| Form DEF 14A Xeris Biopharma Holdings For: Dec 31 | SEC filing · Form DEF | SEC EDGAR | -0.17% | +1.85% | |
| Form DEFA14A Xeris Biopharma Holdings | SEC filing · Form DEFA14A | SEC EDGAR | -0.17% | +1.85% | |
| Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026 | Press release | Business Wire | -0.99% | -1.49% | |
| Form 8-K Xeris Biopharma Holdings For: Apr 20 | SEC filing · Form 8-K | SEC EDGAR | -0.68% | +1.85% | |
| Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | Press release | Business Wire | +0.17% | +0.17% | |
| Form 10-K Xeris Biopharma Holdings For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.95% | +2.24% | |
| Form 8-K Xeris Biopharma Holdings For: Mar 02 | SEC filing · Form 8-K | SEC EDGAR | -1.70% | -14.97% | |
| Form S-8 Xeris Biopharma Holdings | SEC filing · Form S-8 | SEC EDGAR | +0.95% | +2.24% | |
| Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance | Press release | Business Wire | -1.70% | -14.97% | |
| Form 8-K Xeris Biopharma Holdings For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | -0.32% | -5.99% | |
| Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit | Press release | Business Wire | -0.32% | -5.99% | |
| Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026 | Press release | Business Wire | +0.73% | +1.17% | |
| Form 8-K Xeris Biopharma Holdings For: Jan 08 | SEC filing · Form 8-K | SEC EDGAR | +0.26% | +6.69% | |
| Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue | Press release | Business Wire | +0.26% | +6.69% | |
| Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | Press release | Business Wire | -2.27% | -3.27% | |
| Form 8-K Xeris Biopharma Holdings For: Dec 01 | SEC filing · Form 8-K | SEC EDGAR | +1.13% | -1.70% | |
| Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application | Press release | Business Wire | +1.13% | -1.70% | |
| Form 10-Q Xeris Biopharma Holdings For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.66% | -1.33% | |
| Form 8-K Xeris Biopharma Holdings For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | -0.12% | -8.21% | |
| Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025 | Press release | Business Wire | -0.12% | -8.21% | |
| Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025 | Press release | Business Wire | +1.21% | +0.44% | |
| Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | -0.36% | -1.69% | |
| American Regent® Launches Gvoke VialDx™ (glucagon injection) | Press release | PR Newswire | +0.51% | +1.01% | |
| Xeris Announces Orange Book Listing of U.S. Patent for Recorlev® | Press release | Business Wire | +0.51% | -0.13% | |
| Form 10-Q Xeris Biopharma Holdings For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.28% | +2.86% | |
| Form 8-K Xeris Biopharma Holdings For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | -5.15% | -2.94% | |
| Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance | Press release | Business Wire | -5.15% | -2.94% | |
| Xeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025 | Press release | Business Wire | +1.17% | -0.78% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the XERS section they belong to.
Where else XERS is measured.
XERS earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | 256 | +0.04% | 57% |
| Prothena Corporation plc - Ordinary Shares (PRTA) | 256 | -0.04% | 49% |
| Cerus Corporation (CERS) | 255 | +0.09% | 52% |
| Avalon GloboCare Corp. (AVCO) | 254 | 0.00% | 41% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Xeris Biopharma Holdings, Inc.'s median reaction calculated?
Every labeled XERS news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 256 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 57% of XERS's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does XERS's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.